

# CITATION REPORT

List of articles citing

The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinsons disease

DOI: 10.3389/fncom.2013.00013

Frontiers in Computational Neuroscience, 2013, 7, 13.

**Source:** <https://exaly.com/paper-pdf/57222521/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
232	Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?. <b>2013</b> , 251, 2-20		68
231	Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease. <b>2013</b> , 41, 1503-8		29
230	ATP-ases of synaptic plasma membranes in striatum: enzymatic systems for synapses functionality by in vivo administration of L-acetylcarnitine in relation to Parkinson's Disease. <b>2013</b> , 248, 414-26		8
229	Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. <b>2013</b> , 3, 130131		56
228	Striatal dopamine ramping may indicate flexible reinforcement learning with forgetting in the cortico-basal ganglia circuits. <b>2014</b> , 8, 36		25
227	Modeling intracellular signaling underlying striatal function in health and disease. <b>2014</b> , 123, 277-304		13
226	Ageing and Parkinson's disease: why is advancing age the biggest risk factor?. <b>2014</b> , 14, 19-30		487
225	Singular localization of sodium channel $\beta$ subunit in unmyelinated fibres and its role in the striatum. <b>2014</b> , 5, 5525		45
224	A computational model of motor neuron degeneration. <b>2014</b> , 83, 975-88		94
223	Selective increase of in vivo firing frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain. <b>2014</b> , 40, 2898-909		20
222	Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations. <b>2014</b> , 82, 88-100		21
221	The "addicted" spine. <b>2014</b> , 8, 110		35
220	Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. <b>2014</b> , 8, 152		126
219	Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains. <b>2015</b> , 593, 929-46		62
218	Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese. <b>2015</b> , 5, 15891		53
217	Computational modeling of extracellular dopamine kinetics suggests low probability of neurotransmitter release. <b>2015</b> , 69, 515-25		7
216	PGC-1 $\beta$ controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. <b>2015</b> , 7, 629-47		57

215	α-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <b>2015</b> , 5, 2675-700	33
214	Metacognition in Early Phase Psychosis: Toward Understanding Neural Substrates. <b>2015</b> , 16, 14640-54	10
213	Morphological changes of glutamatergic synapses in animal models of Parkinson's disease. <b>2015</b> , 9, 117	40
212	Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits. <b>2014</b> , 8, 242	11
211	A constraint-based modelling approach to metabolic dysfunction in Parkinson's disease. <b>2015</b> , 13, 484-91	4
210	Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. <b>2015</b> , 73, 70-82	59
209	Impaired intracellular trafficking defines early Parkinson's disease. <b>2015</b> , 38, 178-88	127
208	Neurobiological model of stimulated dopamine neurotransmission to interpret fast-scan cyclic voltammetry data. <b>2015</b> , 1599, 67-84	8
207	Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. <b>2015</b> , 40, 200-10	352
206	Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling. <b>2015</b> , 24, 2591-604	16
205	Neurodegeneration: The Size Takes It All. <b>2015</b> , 25, R797-800	4
204	Oxidative Stress in Parkinson's Disease: Role in Neurodegeneration and Targets for Therapeutics. <b>2015</b> , 147-176	1
203	Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis. <b>2015</b> , 589, 3786-94	16
202	Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. <b>2015</b> , 25, 2349-60	248
201	Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. <b>2015</b> , 33, 68-78	77
200	Determinants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease. <b>2016</b> , 24, 821-837	
199	Neuroprotective Transcription Factors in Animal Models of Parkinson Disease. <b>2016</b> , 2016, 6097107	20
198	[Axon arborization size is a key factor influencing cellular bioenergetics and vulnerability of dopamine neurons in Parkinson's disease]. <b>2016</b> , 32, 342-4	1

197	Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics <i>in vivo</i> . <b>2016</b> , 136, 1270-1283	11
196	Implications of cellular models of dopamine neurons for disease. <b>2016</b> , 116, 2815-2830	10
195	Mitochondrial control of cell bioenergetics in Parkinson's disease. <b>2016</b> , 100, 123-137	55
194	Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. <b>2016</b> , 139 Suppl 1, 156-178	85
193	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <b>2016</b> , 42, 77-94	114
192	Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons. <b>2016</b> , 26, 4160-4169	82
191	Cable energy function of cortical axons. <b>2016</b> , 6, 29686	19
190	Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects. <b>2016</b> , 6, 33377	40
189	Is age-related failure of metabolic reprogramming a principal mediator in idiopathic Parkinson's disease? Implications for treatment and inverse cancer risk. <b>2016</b> , 93, 154-60	3
188	Catecholamines and cognition after traumatic brain injury. <b>2016</b> , 139, 2345-71	48
187	Neurological Diseases from a Systems Medicine Point of View. <b>2016</b> , 1386, 221-50	3
186	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. <b>2016</b> , 131, 49-73	125
185	Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder. <i>Molecular Psychiatry</i> , <b>2017</b> , 22, 441-449	15.1 31
184	Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (Synuclein)-Environment (Paraquat) Interactions. <b>2017</b> , 54, 3825-3842	33
183	Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease. <b>2017</b> , 7, 40887	24
182	Selective neuronal vulnerability in Parkinson disease. <b>2017</b> , 18, 101-113	465
181	Parkin functionally interacts with PGC-1 $\alpha$ to preserve mitochondria and protect dopaminergic neurons. <b>2017</b> , 26, 582-598	41
180	Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice. <b>2017</b> , 27, 1048-1066	77

179	Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP. <b>2017</b> , 38, 541-555	42
178	Ventricular fibrillation cardiac arrest produces a chronic striatal hyperdopaminergic state that is worsened by methylphenidate treatment. <b>2017</b> , 142, 305-322	4
177	Parkinson disease. <b>2017</b> , 3, 17013	1700
176	Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. <b>2017</b> , 133, 12-30	60
175	Mutant $\alpha$ Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease. <b>2017</b> , 37, 47-57	20
174	Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1 zebrafish. <b>2017</b> , 45, 528-535	57
173	Microtubule Destabilization Paves the Way to Parkinson's Disease. <b>2017</b> , 54, 6762-6774	22
172	Regulation of autophagy by mitochondrial phospholipids in health and diseases. <b>2017</b> , 1862, 114-129	49
171	Calcium and Parkinson's disease. <b>2017</b> , 483, 1013-1019	118
170	Evaluation of a biologically relevant level of MMW radiation absorption in neuronal tissue. <b>2017</b> ,	0
169	Parkinson Disease: An Evolutionary Perspective. <b>2017</b> , 8, 157	31
168	PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , <b>2017</b> , 10, 120	6.1 53
167	Modulating the catalytic activity of AMPK has neuroprotective effects against $\alpha$ Synuclein toxicity. <b>2017</b> , 12, 80	26
166	Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy. <b>2017</b> , 23, 776-783	13
165	Parkinson's disease genetic risk in a midbrain neuronal cell line. <b>2018</b> , 114, 53-64	23
164	Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease. <b>2018</b> , 8, 161-181	61
163	Dopamine Secretion Is Mediated by Sparse Active Zone-like Release Sites. <b>2018</b> , 172, 706-718.e15	102
162	The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease. <b>2018</b> , 33, 196-207	29

161	Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate. <b>2018</b> , 7, 5-11	33
160	Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons. <b>2018</b> , 293, 9580-9593	23
159	Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. <b>2018</b> , 115, 80-91	173
158	An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. <b>2018</b> , 92, 41-82	51
157	Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease. <b>2018</b> , 12, 440	22
156	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <b>2018</b> , 17, 804-822	114
155	Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. <b>2018</b> , 8, 479-493	25
154	Ferritin and neuromelanin "quantum dot" array structures in dopamine neurons of the substantia nigra pars compacta and norepinephrine neurons of the locus coeruleus. <b>2018</b> , 171, 48-58	7
153	On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. <b>2018</b> , 9, 455	137
152	Mechanisms of $\alpha$ Synuclein Induced Synaptopathy in Parkinson's Disease. <b>2018</b> , 12, 80	158
151	LRRK2 and mitochondria: Recent advances and current views. <b>2019</b> , 1702, 96-104	51
150	Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. <b>2019</b> , 18, e13031	158
149	Role of Dietary Supplements in the Management of Parkinson's Disease. <b>2019</b> , 9,	26
148	Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. <b>2019</b> , 14, 29	135
147	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. <b>2019</b> , 34, 1406-1422	37
146	NEUROPROTECTIVE IMMUNITY: Leukaemia Inhibitory Factor (LIF) as guardian of brain health. <b>2019</b> , 2, 100006	3
145	Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. <b>2019</b> , 15, e1008352	30
144	Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter. <b>2019</b> , 10, 4263	23

143	The Energy Homeostasis Principle: Neuronal Energy Regulation Drives Local Network Dynamics Generating Behavior. <i>Frontiers in Computational Neuroscience</i> , <b>2019</b> , 13, 49	3.5	28
142	Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease. <b>2019</b> , 49, 561-589		13
141	Neuronal Mitophagy: Lessons from a Pathway Linked to Parkinson's Disease. <b>2019</b> , 36, 292-305		9
140	Unbalanced calcium channel activity underlies selective vulnerability of nigrostriatal dopaminergic terminals in Parkinsonian mice. <b>2019</b> , 9, 4857		10
139	Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities. <b>2019</b> , 6, 406-415		4
138	Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity. <b>2019</b> , 24, 120-138		5
137	Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. <b>2019</b> , 7, 41		77
136	Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality. <b>2019</b> , 12, 878-889		37
135	Activation of the Rostral Intralaminar Thalamus Drives Reinforcement through Striatal Dopamine Release. <b>2019</b> , 26, 1389-1398.e3		23
134	Mechanisms and regulation of dopamine release. <b>2019</b> , 57, 46-53		31
133	A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity. <b>2019</b> , 13, 11		20
132	NCS-1 Deficiency Affects mRNA Levels of Genes Involved in Regulation of ATP Synthesis and Mitochondrial Stress in Highly Vulnerable Dopaminergic Neurons. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 252	6.1	8
131	AMP Kinase Activation is Selectively Disrupted in the Ventral Midbrain of Mice Deficient in Parkin or PINK1 Expression. <b>2019</b> , 21, 25-32		6
130	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. <b>2019</b> , 59, 263-289		41
129	SEAweb: the small RNA Expression Atlas web application. <b>2020</b> , 48, D204-D219		9
128	Heterogeneity of dopamine release sites in health and degeneration. <b>2020</b> , 134, 104633		12
127	A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease. <b>2020</b> , 14, 34		5
126	Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. <b>2020</b> , 9, 39		7

125	Calcium, Bioenergetics, and Parkinson's Disease. <b>2020</b> , 9,	23
124	Mitophagy and the Brain. <b>2020</b> , 21,	13
123	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease. <b>2020</b> , 8, 580634	12
122	Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases. <b>2020</b> , 11, 371	9
121	Nutraceuticals Targeting Generation and Oxidant Activity of Peroxynitrite May Aid Prevention and Control of Parkinson's Disease. <b>2020</b> , 21,	10
120	The Evolution-Driven Signature of Parkinson's Disease. <b>2020</b> , 43, 475-492	8
119	Analysis of Quinone Reductase 2 Implication in Mechanism of Antiparkinsonian Action of Afobazole. <b>2020</b> , 14, 227-234	2
118	Upper Limit on the Thermodynamic Information Content of an Action Potential. <i>Frontiers in Computational Neuroscience</i> , <b>2020</b> , 14, 37	3.5 6
117	Parkinson's disease treatment: past, present, and future. <b>2020</b> , 127, 785-791	12
116	Selective neuronal vulnerability in Parkinson's disease. <b>2020</b> , 252, 61-89	12
115	Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause?. <b>2020</b> , 14, 213	62
114	Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic. <b>2021</b> , 133, 9299-9330	4
113	Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic. <b>2021</b> , 60, 9215-9246	24
112	Energy sensors in drug addiction: A potential therapeutic target. <b>2021</b> , 26, e12936	3
111	Dopamine Transporter Localization in Medial Forebrain Bundle Axons Indicates Its Long-Range Transport Primarily by Membrane Diffusion with a Limited Contribution of Vesicular Traffic on Retromer-Positive Compartments. <b>2021</b> , 41, 234-250	3
110	Perspective: Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin. <b>2021</b> , 12, 355-362	7
109	Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration. <b>2021</b> , 11, 1754	7
108	Monkey Brains [Evolution of the human brain and the vulnerability of the substantia nigra. <b>2021</b> , 181-191	



107	The therapeutic potential of ketone bodies in Parkinson's disease. <b>2021</b> , 21, 255-257	1
106	Biomarkers of Neurotoxicity Inform Mechanisms of Vulnerability and Resilience in Dopaminergic Neurons. <b>2021</b> , 1-15	0
105	Metabolomics in Parkinson's disease. <b>2021</b> , 104, 107-149	0
104	Cardiorespiratory and Endocrine Mechanisms Behind the Effectiveness of Pranayama. <b>2021</b> , 49-60	
103	A Multiscale, Systems-level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching under Normal, Parkinsonian and Levodopa Medication Conditions.	1
102	Artificial Neurovascular Network (ANVN) to Study the Accuracy Vs. Efficiency trade-off in an Energy Dependent Neural Network.	
101	Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle. <b>2021</b> , 13,	16
100	LRRK2 at the Crossroad of Aging and Parkinson's Disease. <b>2021</b> , 12,	3
99	Novel insights in the pathophysiology of $\alpha$ -Synuclein dysregulation on D2 receptor activity contributing to the vulnerability of dopamine neurons.	
98	Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution.	
97	Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of $\alpha$ -Synuclein and Cholesterol. <b>2021</b> , 15, 658244	2
96	Nanomedicine against Alzheimer's and Parkinson's Disease. <b>2021</b> , 27, 1507-1545	3
95	Wave-like dopamine dynamics as a mechanism for spatiotemporal credit assignment. <b>2021</b> , 184, 2733-2749.e163	3
94	Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson disease-linked genes.	3
93	Bilirubin: A Promising Therapy for Parkinson's Disease. <b>2021</b> , 22,	0
92	Artificial neurovascular network (ANVN) to study the accuracy vs. efficiency trade-off in an energy dependent neural network. <b>2021</b> , 11, 13808	2
91	Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease. <b>2021</b> , 9,	8
90	Mechanistic model-driven exometabolomic characterisation of human dopaminergic neuronal metabolism.	0

89	Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons. <b>2021</b> , 156, 105409	2
88	βSynuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. <b>2021</b> , 7, 76	1
87	The Thermodynamic Consequences of Parkinson's Disease. <b>2021</b> , 12, 685314	0
86	Subcellular and regional localization of mRNA translation in midbrain dopamine neurons.	1
85	Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution. <b>2021</b> , 54, 6618-6632	3
84	Astrocytes, a Promising Opportunity to Control the Progress of Parkinson's Disease. <b>2021</b> , 9,	3
83	Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study. <b>2021</b> , 100, e24191	7
82	Diverse midbrain dopaminergic neuron subtypes and implications for complex clinical symptoms of Parkinson's disease. <b>2021</b> , 1,	0
81	Axonal mechanisms mediating GABA-A receptor inhibition of striatal dopamine release.	2
80	Influence of Energy Deficiency on the Molecular Processes of Substantia Nigra Pars Compacta Cell for Understanding Parkinsonian Neurodegeneration: A Comprehensive Biophysical Computational Model.	3
79	A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease.	2
78	A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease.	5
77	A computational model of loss of dopaminergic cells in Parkinson's disease due to glutamate-induced excitotoxicity.	2
76	Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter.	1
75	Autism Spectrum Disorders: Multiple Routes to, and Multiple Consequences of, Abnormal Synaptic Function and Connectivity. <b>2021</b> , 27, 10-29	5
74	Forgetting in Reinforcement Learning Links Sustained Dopamine Signals to Motivation. <b>2016</b> , 12, e1005145	22
73	Simple models including energy and spike constraints reproduce complex activity patterns and metabolic disruptions. <b>2020</b> , 16, e1008503	4
72	Brain energetics, mitochondria, and traumatic brain injury. <b>2020</b> , 31, 363-390	4

71	Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms. <b>2018</b> , 16, 484-504	16
70	Cellular Senescence in Neurodegenerative Diseases. <b>2020</b> , 14, 16	78
69	Coordination of rapid cholinergic and dopaminergic signaling in striatum during spontaneous movement. <b>2019</b> , 8,	28
68	Axonal mechanisms mediating $\gamma$ -aminobutyric acid receptor type A (GABA-A) inhibition of striatal dopamine release. <b>2020</b> , 9,	16
67	Encyclopedia of Computational Neuroscience. <b>2013</b> , 1-10	
66	Encyclopedia of Computational Neuroscience. <b>2014</b> , 1-10	
65	Life on the Edge: Determinants of Selective Neuronal Vulnerability in Parkinson's Disease. <b>2016</b> , 141-173	
64	SEA: The small RNA Expression Atlas.	
63	Encyclopedia of Computational Neuroscience. <b>2018</b> , 1-12	
62	Formal model of Parkinson's disease neurons unveils possible causality links in the pathophysiology of the disease.	
61	Dopamine Release Neuroenergetics in Mouse Striatal Slices.	
60	Energy regulation and Parkinson's disease. <b>2020</b> , 205-220	
59	Vagal motoneurons in Parkinson's disease. <b>2020</b> , 327-343	0
58	Functional neural electron transport. <b>2020</b> , 25-111	0
57	Simple models including energy and spike constraints reproduce complex activity patterns and metabolic disruptions.	
56	Disruption of Mitochondrial Homeostasis: The Role of PINK1 in Parkinson's Disease. <b>2021</b> , 10,	2
55	Mitochondrial-nuclear cross-talk in the human brain is modulated by cell type and perturbed in neurodegenerative disease. <b>2021</b> , 4, 1262	1
54	Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease: removing axonal debris. <b>2021</b> , 10, 43	3

53	Mitochondrial dysfunction as a trigger of programmed axon death. <b>2021</b> ,		3
52	The Dopamine System and Automatization of Movement Sequences: A Review With Relevance for Speech and Stuttering.. <b>2021</b> , 15, 661880		0
51	Mechanisms of -Mediated Neurodegeneration in Parkinson's Disease.. <b>2021</b> , 2, 221-244		1
50	Subcellular proteomics of dopamine neurons in the mouse brain.. <b>2022</b> , 11,		4
49	A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions.. <i>Frontiers in Computational Neuroscience</i> , <b>2021</b> , 15, 756881	3.5	1
48	iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.. <b>2022</b> , 29, 189-208		4
47	The Netrin-1 Receptor DCC Promotes the Survival of a Subpopulation of Midbrain Dopaminergic Neurons: Relevance for Ageing and Parkinson's Disease.. <b>2022</b> ,		1
46	Fluid markers of synapse degeneration in synucleinopathies.. <b>2022</b> , 129, 187		0
45	Microbes and Parkinson's disease: from associations to mechanisms.. <b>2022</b> ,		1
44	Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active.. <b>2022</b> , 16, 826193		2
43	The potential applications of traditional Chinese medicine in Parkinson's disease: A new opportunity.. <b>2022</b> , 149, 112866		0
42	Ubiquitin Proteasome System and Microtubules Are Master Regulators of Central and Peripheral Nervous System Axon Degeneration.. <b>2022</b> , 11,		
41	Coronavirus Disease 2019 and related Parkinsonism: the clinical evidence thus far.		5
40	A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.. <b>2022</b> , 16, 797127		0
39	CHAPTER 2. Oxidative Stress and Redox Signalling in the Parkinson's Disease Brain. 27-60		
38	Image_1.TIF. <b>2018</b> ,		
37	Image_2.TIF. <b>2018</b> ,		
36	Image_3.TIF. <b>2018</b> ,		

35	Image_4.TIF. <b>2018</b> ,		
34	Image_5.TIF. <b>2018</b> ,		
33	Image_6.TIF. <b>2018</b> ,		
32	Data_Sheet_1.pdf. <b>2019</b> ,		
31	Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells. <i>Molecular Psychiatry</i> ,	15.1	1
30	Chronic di(2-ethylhexyl) phthalate exposure leads to dopaminergic neuron degeneration through mitochondrial dysfunction in <i>C. elegans</i> . <i>Environmental Pollution</i> , <b>2022</b> , 119574	9.3	0
29	Linking $\alpha$ -synuclein induced synaptopathy and neural network dysfunction in early Parkinson's disease. <i>Brain Communications</i> ,	4.5	0
28	Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. <i>Frontiers in Aging</i> , 3,	2.5	0
27	Regulation of Oxidative Stress by Long Non-coding RNAs in Central Nervous System Disorders. <i>Frontiers in Molecular Neuroscience</i> , 15,	6.1	
26	Parkinson's Disease: Deep Brain Stimulation. <b>2022</b> , 2599-2611		
25	Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson's Disease Pathogenesis and Treatment. <i>Frontiers in Aging Neuroscience</i> , 14,	5.3	
24	The Role of Rab Proteins in Parkinson's Disease Synaptopathy. <b>2022</b> , 10, 1941		1
23	Electrophysiology and Single Cells. <b>2022</b> , 251-272		0
22	Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism. <b>2022</b> , 63-89		5
21	Methamphetamine Self-Administration Differential Effects on Mesolimbic Glutathione Levels, Mitochondrial Respiration and Dopamine Neuron Firing Activity.		0
20	Exploring plausible therapeutic targets for Alzheimer's disease using multi-omics approach, machine learning and docking. <b>2022</b> , 22,		1
19	Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease. <b>2022</b> , 11, 1780		1
18	Ca <sup>2+</sup> channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons. <b>2022</b> , 8,		1

- 17 Axonal domain structure as a putative identifier of neuron-specific vulnerability to oxidative stress in cultured neurons. *ENEURO*.0139-22.2022 ○
- 16 Effects of Global Warming on Patients with Dementia, Motor Neuron or Parkinson's Diseases: A Comparison among Cortical and Subcortical Disorders. **2022**, 19, 13429 ○
- 15 Single-cell and single-nuclei RNA sequencing as powerful tools to decipher cellular heterogeneity and dysregulation in neurodegenerative diseases. 10, ○
- 14 Calcium Channels and Selective Neuronal Vulnerability in Parkinson's Disease. **2022**, 575-598 ○
- 13 The complex role of inflammation and gliotransmitters in Parkinson's disease. **2023**, 176, 105940 ○
- 12 Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts. 1
- 11 Parkin regulates neuronal lipid homeostasis through SREBP2-lipoprotein lipase pathway—Implications for Parkinson's disease. ○
- 10 Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition. 1
- 9 Biomarkers of Neurotoxicity Inform Mechanisms of Vulnerability and Resilience in Dopaminergic Neurons. **2022**, 223-237 ○
- 8 Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson's Disease Models by Alleviating Oxidative Stress. **2023**, 12, 153 1
- 7 Brain developmental trajectories associated with childhood stuttering persistence and recovery. **2023**, 60, 101224 ○
- 6 Long-term methamphetamine self-administration increases mesolimbic mitochondrial oxygen consumption and decreases striatal glutathione. **2023**, 227, 109436 ○
- 5 Disease mechanisms as Subtypes: Mitochondrial and bioenergetic dysfunction. **2023**, 53-66 ○
- 4 Impaired dopamine release in Parkinson's disease. ○
- 3 Development of Small Molecules Targeting  $\alpha$ -Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease. **2023**, 15, 839 ○
- 2 SK and Kv4 Channels Limit Spike Timing Perturbations in Pacemaking Dopamine Neurons. **2023**, 10, ENEURO.0445-22.2023 ○
- 1 Genetic Evidence for Endolysosomal Dysfunction in Parkinson's Disease: A Critical Overview. **2023**, 24, 6338 ○